Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Johnson & Johnson names proposed consumer health spinoff ‘Kenvue’ 

By Brian Buntz | September 28, 2022

Johnson & JohnsonJohnson & Johnson (NYSE:JNJ) has announced that it will name its consumer health division “Kenvue.”

Earlier this year, GSK (NYSE:GSK) made a similar move by naming its consumer healthcare segment “Haleon.” That moniker fuses the old English word ‘hale’ with the name “Leon.” The first word means ‘healthy’ while the second refers to “strength.”

Haleon became a separate unit in July 2022.

Similarly, Kenvue brings together the words “ken,” meaning “knowledge,” and “vue,” meaning “sight.”

Johnson & Johnson has signaled its intent to spin off Kenvue by November 2023.

The remaining company, headquartered in New Brunswick, New Jersey, would continue to focus on its drug and device businesses.

“Unveiling the Kenvue brand is a defining moment for our stakeholders and an important part of the planned separation,” said Thibaut Mongon, CEO Designate, Kenvue, in a news release. “We breathe life into some of the world’s most iconic and beloved brands every day, so we harnessed that same expertise, love, and energy into developing our new corporate identity.”

“Today’s announcement is another milestone for the Consumer Health business,” said Johnson & Johnson CEO Joaquin Duato in a statement. “Kenvue is poised to thrive as a standalone company with a leading portfolio of brands consumers love and trust. I’m confident in this team and excited to see what the future holds.”

Pending regulatory approval, Kenvue would become one of the largest consumer health companies. Its portfolio would include brands such as Aveeno, Band-Aid, Listerine, Neutrogena and Tylenol.

A more than $14-billion-a-year business

In 2021, Johnson & Johnson’s consumer health unit generated revenue of $14.6 billion.

By contrast, its pharmaceutical unit Janssen had $52.1 billion in sales.

While Johnson & Johnson’s consumer unit has faced lawsuits in recent years related to talcum powder, its drug division has faced a wave of litigation related to opioids. Johnson & Johnson recently agreed to pay $39 million to settle New Hampshire opioid allegations. It has reached similar deals with several other U.S. states.

After announcing the plan, the company’s stock ticked up 0.86% to $166.36.

Criticism over J&J’s ‘Texas two-step’

J&J has faced scrutiny over a complex maneuver nicknamed the “Texas two-step.” Critics allege that J&J is seeking to shield itself from billions of dollars worth of lawsuit payouts involving people who claim J&J’s talc-based baby powder caused them to develop cancer.

A recent New Yorker expose detailed how J&J created a new LLC called LTL Management and then moved the talc liability over to LTL. The new LLC has since filed for Chapter 11 bankruptcy protection. Calling the bankruptcy a “shell game,” plaintiffs in the talc lawsuits have appealed — with the U.S. Court of Appeals for the Third Circuit holding expedited hearings this month.

About The Author

Brian Buntz

The pharma and biotech editor of WTWH Media, Brian is a veteran journalist with more than 15 years of experience covering an array of life science topics, including clinical trials, drug discovery and development and medical devices. Before coming to WTWH, he served as content director focused on connected devices at Informa. In addition, Brian covered the medical device sector for 10 years at UBM. At Qmed, he overhauled the brand’s news coverage and helped to grow the site’s traffic volume dramatically. He had previously held managing editor roles on two of the company’s medical device technology publications. Connect with him on LinkedIn or email at bbuntz@wtwhmedia.com.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Genentech roche
Roche, Genentech to build $700M drug manufacturing plant in North Carolina
These are the logos of Otsuka Medical and ICU Medical.
ICU Medical, Otsuka Pharmaceutical Factory launch joint IV supply chain venture
Amgen
Amgen to spend $900M to expand U.S. biopharma manufacturing
Roche
Roche to invest $50B in U.S. over next five years
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE